Betaine
|
Basic information |
| Metabolite name | Betaine |
 | HMDB0000043 |
 |
C00719 |
 |
247 |
| Synonyms | N,N,N-trimethylglycinium |
| No. of studies | 37 |
|
Basic information |
| Metabolite name | Betaine |
| HMDB0000043 |
|
C00719 |
|
247 |
| Synonyms | N,N,N-trimethylglycinium |
| No. of studies | 37 |
|
Relationship between Betaine and depression (count: 37) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M014 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M014 | Type2 | CUMS + XY-A group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M032 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M050 | Type3 | 14h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M050 | Type3 | 2h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M072 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M072 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Down |
| Study M077 | Type1 | non-weaned group vs. weaned group | Urine | Wistar rat | Down |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1044 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M1056 | Type1 | maternal separation group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Up |
| Study M1097 | Type2 | probiotic-treated depression group vs. placebo-treated depression group | Faece | Human | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M116 | Type3 | ketamine group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Down |
| Study M146 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M146 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M146 | Type2 | CUMS + middle dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + high dose of SSO group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M146 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Medial prefrontal cortex | C57BL/6 J mouse | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Down |
| Study M647 | Type1 | antepartum depression group vs. control group | Plasma | Human | Down |
| Study M661 | Type1 | PSD group vs. stroke group | Plasma | Human | Down |
| Study M712 | Type1 | depression group vs. control group | Liver | Cynomolgus monkey | Down |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Up |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Up |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M869 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M869 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M926 | Type1 | CSDS group vs. control group | Cerebrospinal fluid | C57BL/6 J mouse | Down |